KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Common Equity (2016 - 2025)

Acadia Pharmaceuticals has reported Common Equity over the past 16 years, most recently at $1.2 billion for Q4 2025.

  • Quarterly results put Common Equity at $1.2 billion for Q4 2025, up 67.49% from a year ago — trailing twelve months through Dec 2025 was $1.2 billion (up 67.49% YoY), and the annual figure for FY2025 was $1.2 billion, up 67.49%.
  • Common Equity for Q4 2025 was $1.2 billion at Acadia Pharmaceuticals, up from $917.3 million in the prior quarter.
  • Over the last five years, Common Equity for ACAD hit a ceiling of $1.2 billion in Q4 2025 and a floor of $362.2 million in Q3 2023.
  • Median Common Equity over the past 5 years was $528.8 million (2021), compared with a mean of $577.4 million.
  • Biggest five-year swings in Common Equity: dropped 25.97% in 2022 and later surged 69.72% in 2024.
  • Acadia Pharmaceuticals' Common Equity stood at $540.9 million in 2021, then dropped by 25.97% to $400.4 million in 2022, then grew by 7.83% to $431.8 million in 2023, then surged by 69.72% to $732.8 million in 2024, then skyrocketed by 67.49% to $1.2 billion in 2025.
  • The last three reported values for Common Equity were $1.2 billion (Q4 2025), $917.3 million (Q3 2025), and $822.4 million (Q2 2025) per Business Quant data.